Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SS18
REST API REST API
Homo sapiens
SS18 is differentially expressed in 328 experiments: 147 organism parts: bone marrow, lung, ... (145 more);, 247 disease states: normal, acute promyelocytic leukemia, ... (245 more);, 116 cell types 499 cell lines 46 compound treatments and 81 other conditions.
Synonyms SYT, SSXT
Orthologs Q5ZMA8_CHICK (Gallus gallus)   A5D7A1_BOVIN (Bos taurus)   Ss18 (Mus musculus)   Ss18 (Rattus norvegicus)   ss18 (Xenopus laevis)   SS18 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytoskeleton organization, protein binding, regulation of transcription, DNA-dependent, cell morphogenesis, positive regulation of transcription from RNA polymerase II promoter, nucleus, cytoplasmic microtubule, ligand-dependent nuclear receptor transcription coactivator activity, response to drug, microtubule cytoskeleton organization, intracellular protein kinase cascade, ephrin receptor signaling pathway
InterPro Term SSXT
UniProt Accession Q15532, Q6FGL9, B4E2J6, B4DR34, Q4VAX0, B4DLD3, F5GWN1
Search EB-eye ENSG00000141380
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-7540, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (43 experiments)

Factor Value U/D Experiments
BT474
3
E-MEXP-440, E-MTAB-37, E-MTAB-62
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
BT20
2
E-MTAB-37, E-MTAB-62
KG1
2
E-GEOD-24147, E-MTAB-37
LNCaP
2
E-GEOD-14990, E-GEOD-14464
493 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (53 experiments)

Factor Value U/D Experiments
monocyte
1
3
E-GEOD-22373, E-GEOD-995, E-MEXP-2019, E-GEOD-11755
CD8+ T cell
2
E-TABM-145, E-AFMX-5
testis - germ cell
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
bronchial epithelial
2
E-AFMX-5, E-MTAB-25
721 B lymphoblast
2
2
E-AFMX-5, E-TABM-145
110 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (71 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-MEXP-2034, E-MTAB-62, E-GEOD-96
rhabdomyosarcoma
2
E-MTAB-62, E-MTAB-37
astrocytoma
2
E-MTAB-37, E-GEOD-4290
colon carcinoma
2
E-MTAB-37, E-MTAB-62
dermatomyositis
2
E-MTAB-62, E-GEOD-5370
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
241 more value(s).


Compound treatment

studied in E-GEOD-1417, E-GEOD-697, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (29 experiments)

Factor Value U/D Experiments
none
2
9
E-GEOD-5824, E-MEXP-1958, E-GEOD-412, E-TABM-868, E-MEXP-1230, ... (11 experiments)
control
3
E-GEOD-3284, E-GEOD-4006, E-GEOD-5339
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
saline
1
E-GEOD-3026
AMP
1
1
E-MEXP-2285
40 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
DMSO
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-MEXP-2280, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-GEOD-6431, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, ... (12 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-TABM-127, E-GEOD-20540, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (44 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12254, E-GEOD-9723, E-MEXP-561, E-GEOD-17400, ... (6 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-7819, E-GEOD-19703, E-GEOD-21750, E-GEOD-5824, E-GEOD-6434, ... (10 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343, ... (6 experiments)

Replicate
studied in E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-MEXP-1509, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922, E-TABM-147

Vehicle
studied in E-GEOD-5258

Processing time: 0.499 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM